Anthony Neuger

1.8k total citations
29 papers, 1.4k citations indexed

About

Anthony Neuger is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anthony Neuger has authored 29 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anthony Neuger's work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Research Studies (4 papers) and Cancer therapeutics and mechanisms (4 papers). Anthony Neuger is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Research Studies (4 papers) and Cancer therapeutics and mechanisms (4 papers). Anthony Neuger collaborates with scholars based in United States and Italy. Anthony Neuger's co-authors include Richard M. Lush, Scott Antonia, Dmitry I. Gabrilovich, Mary Dunn, Ingo Fricke, Mayer Fishman, Noweeda Mirza, Daniel M. Sullivan, Hatem Soliman and Alberto Chiappori and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Anthony Neuger

29 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anthony Neuger United States	15	635	541	502	179	122	29	1.4k
Norma Hernández‐Pedro Mexico	20	587 0.9×	339 0.6×	214 0.4×	184 1.0×	234 1.9×	50	1.3k
Inge Tinhofer Austria	22	689 1.1×	427 0.8×	393 0.8×	76 0.4×	176 1.4×	50	1.4k
Xiaoming Shen China	20	533 0.8×	477 0.9×	143 0.3×	250 1.4×	182 1.5×	34	1.2k
Judit Dobos Hungary	18	443 0.7×	377 0.7×	192 0.4×	97 0.5×	155 1.3×	33	989
Georgios Kallifatidis United States	18	940 1.5×	646 1.2×	214 0.4×	124 0.7×	364 3.0×	26	1.7k
Haineng Xu China	17	560 0.9×	346 0.6×	238 0.5×	87 0.5×	220 1.8×	30	1.1k
Leisl Packer Australia	16	815 1.3×	333 0.6×	163 0.3×	63 0.4×	112 0.9×	28	1.1k
Debdutta Bandyopadhyay United States	20	1.1k 1.8×	488 0.9×	291 0.6×	105 0.6×	176 1.4×	34	1.6k
Anna Garuti Italy	21	644 1.0×	477 0.9×	297 0.6×	117 0.7×	254 2.1×	67	1.5k
Sara Rezzola Italy	22	764 1.2×	128 0.2×	237 0.5×	91 0.5×	207 1.7×	42	1.5k

Countries citing papers authored by Anthony Neuger

Since Specialization

Citations

This map shows the geographic impact of Anthony Neuger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Neuger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Neuger more than expected).

Fields of papers citing papers by Anthony Neuger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Neuger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Neuger. The network helps show where Anthony Neuger may publish in the future.

Co-authorship network of co-authors of Anthony Neuger

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Neuger. A scholar is included among the top collaborators of Anthony Neuger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Neuger. Anthony Neuger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saltos, Andreas, Ben Creelan, Tawee Tanvetyanon, et al.. (2023). A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 183. 107313–107313. 3 indexed citations

Neuger, Anthony, et al.. (2018). Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide. Anti-Cancer Drugs. 30(1). 65–71. 9 indexed citations

Mahipal, Amit, Sri Harsha Tella, Anuhya Kommalapati, et al.. (2018). Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Investigational New Drugs. 37(3). 473–481. 11 indexed citations

Tauro, Marilena, Gemma Shay, Antonio Laghezza, et al.. (2017). Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth. Molecular Cancer Therapeutics. 16(3). 494–505. 28 indexed citations

Mahipal, Amit, Jason Klapman, Shivakumar Vignesh, et al.. (2016). Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. Cancer Chemotherapy and Pharmacology. 78(1). 157–165. 41 indexed citations

Perez, Lia, Hugo F. Fernández, Ernesto Ayala, et al.. (2016). Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors. Bone Marrow Transplantation. 52(4). 627–629. 2 indexed citations

Springett, Gregory M., Kazim Husain, Anthony Neuger, et al.. (2015). A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia. EBioMedicine. 2(12). 1987–1995. 65 indexed citations

Mahipal, Amit, Gregory M. Springett, Nancy J. Burke, et al.. (2015). Phase I trial of enzalutamide, gemcitabine, and nab-paclitaxel as a first-line treatment for advanced pancreatic cancer.. Journal of Clinical Oncology. 33(15_suppl). e15250–e15250. 2 indexed citations

Pan, Edward, Daohai Yu, Xiuhua Zhao, et al.. (2014). Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. Journal of Neuro-Oncology. 119(2). 413–420. 4 indexed citations

10.

Mediavilla-Varela, Melanie, Kimberly A. Luddy, David Noyes, et al.. (2013). Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biology & Therapy. 14(9). 860–868. 81 indexed citations

11.

Jackson, Erica L., Susan Minton, Roohi Ismail‐Khan, et al.. (2012). A phase I study of 1-methyl-D-tryptophan in combination with docetaxel in metastatic solid tumors.. Journal of Clinical Oncology. 30(15_suppl). TPS2620–TPS2620. 4 indexed citations

12.

Perkins, Janelle, Steven C. Goldstein, Jana L. Dawson, et al.. (2011). Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates. Clinical Cancer Research. 17(24). 7743–7753. 3 indexed citations

13.

Garrett, Christopher R., Domenico Coppola, Robert M. Wenham, et al.. (2010). Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Investigational New Drugs. 29(6). 1381–1389. 67 indexed citations

14.

Gray, Jhanelle E., Eric B. Haura, Alberto Chiappori, et al.. (2010). Phase I study of LBH589 in combination with erlotinib for advanced aerodigestive tract cancers.. Journal of Clinical Oncology. 28(15_suppl). e13016–e13016. 2 indexed citations

15.

Daud, Adil, Jana L. Dawson, Ronald C. DeConti, et al.. (2009). Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Clinical Cancer Research. 15(7). 2479–2487. 78 indexed citations

16.

Husain, Kazim, R François, Anthony Neuger, et al.. (2009). Vitamin E δ-Tocotrienol Levels in Tumor and Pancreatic Tissue of Mice after Oral Administration. Pharmacology. 83(3). 157–163. 44 indexed citations

17.

Münster, Pamela N., Douglas C. Marchion, Elona Biçaku, et al.. (2009). Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. Clinical Cancer Research. 15(7). 2488–2496. 119 indexed citations

18.

Moulder, Stacy L., Anthony Neuger, Jimin Choi, et al.. (2008). Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer. 113(10). 2646–2654. 15 indexed citations

19.

Chiappori, Alberto, et al.. (2008). Phase I trial evaluating the epidermal growth factor receptor inhibitor erlotinib in combination with the SRC kinase inhibitor dasatinib for patients with recurrent non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 14605–14605. 7 indexed citations

20.

Husain, Kazim, R François, Anthony Neuger, et al.. (2008). Pancreatic Tissue Distribution, Pharmacokinetics and Toxicity of Bioactive delta‐tocotrienol, a Potential Anti‐tumor Bioactive Food Component, in Mice. The FASEB Journal. 22(S1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact